AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vir Biotechnology, Inc. Director's Dealing 2021

Feb 12, 2021

32538_dirs_2021-02-12_b22b46da-855d-4b1b-8e59-dff8441c30a5.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 5 — Annual Statement of Changes in Beneficial Ownership

Issuer: Vir Biotechnology, Inc. (VIR)
CIK: 0001706431
Period of Report: 2020-12-31

Reporting Person: SCANGOS GEORGE A (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-02	Common Stock	G	115000	$0.00	Disposed	4598559	Direct
2020-12-02	Common Stock	G	115000	$0.00	Acquired	115000	Indirect
2020-12-28	Common Stock	G	100000	$0.00	Disposed	4498559	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1907329	Indirect

Footnotes

F1: The shares are held in the name of the Scangos 2018 Grandchildren's Trust, of which the reporting person and his spouse are Trustees.

F2: The shares are held in the name of the George A. Scangos 2018 Annuity Trust dated August 30, 2018, of which the reporting person and his spouse are Trustees.